Basum will implement a strategic plan to scale and standardize product development and corporate operations.
FREMONT, CA: STENTiT, a medical device company bringing an innovative class of regenerative stents for sustained endovascular repair, recently announced the appointment of Dr. Golo von Basum as its Chief Operating Officer (COO). Basum will implement a strategic plan to scale and standardize product development and corporate operations.
Bart Sanders, CEO of STENTiT, said: "We are excited to have Golo joining the team. His background and wealth of experience perfectly fits the current strategic stage of the company aiming at further growth and maturity. This will certainly help us to define the next generation in regenerative stent technology and to become the new standard of care for patients in need of endovascular interventions."
STENTiT welcomes Basum, who has more than 16 years of experience in medical device development. Basum was Site Leader and Head of R&D of numerous divisions within Philips, a global leader in health technology, after receiving his Ph.D. in applied physics for laser spectroscopy and a career in corporate research for care and health applications. He created a clear and pragmatic approach to end-to-end product development procedures in his past employment. Basum has over 30 patents and scientific papers to his credit, has managed multimillion-euro projects, directed teams of over 370 people, and has received FDA and CE medical device approvals.
"In my entire career I am driven by purposeful innovation, and this is exactly what I found at STENTiT. Im proud and honored to become a member of STENTiTs management team. The companys technology addresses the unmet need of sustained vascular repair, with a novel concept of regenerative stents. Hereby the company aims to improve long-term outcomes by leaving behind a restored artery to last a lifetime. STENTiT is uniquely positioned to make a meaningful difference in the lives of patients," adds Golo von Basum, new COO, STENTiT.